144 related articles for article (PubMed ID: 8879803)
21. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients.
Chryssanthou E; Torssander J; Petrini B
Scand J Infect Dis; 1995; 27(4):391-5. PubMed ID: 8658076
[TBL] [Abstract][Full Text] [Related]
22. Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus.
Baily GG; Moore CB; Essayag SM; de Wit S; Burnie JP; Denning DW
Clin Infect Dis; 1997 Jul; 25(1):161-3. PubMed ID: 9243058
[No Abstract] [Full Text] [Related]
23. Comparison of therapeutic activity of fluconazole and itraconazole in the treatment of oesophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study.
Barbaro G; Di Lorenzo G
Ital J Gastroenterol; 1995 May; 27(4):175-80. PubMed ID: 8520033
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.
Maenza JR; Keruly JC; Moore RD; Chaisson RE; Merz WG; Gallant JE
J Infect Dis; 1996 Jan; 173(1):219-25. PubMed ID: 8537662
[TBL] [Abstract][Full Text] [Related]
25. Resistant candidiasis.
Powderly WG
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):925-9. PubMed ID: 7811544
[TBL] [Abstract][Full Text] [Related]
26. Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug.
Venkateswarlu K; Denning DW; Manning NJ; Kelly SL
FEMS Microbiol Lett; 1995 Sep; 131(3):337-41. PubMed ID: 7557345
[TBL] [Abstract][Full Text] [Related]
27. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review.
White A; Goetz MB
Clin Infect Dis; 1994 Oct; 19(4):687-92. PubMed ID: 7803633
[TBL] [Abstract][Full Text] [Related]
28. The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole.
Ohtsuka K; Watanabe M; Orikasa Y; Inouye S; Uchida K; Yamaguchi H; Kondo S; Takeuchi T
J Antimicrob Chemother; 1997 Jan; 39(1):71-7. PubMed ID: 9044030
[TBL] [Abstract][Full Text] [Related]
29. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients.
Lake DE; Kunzweiler J; Beer M; Buell DN; Islam MZ
Chemotherapy; 1996; 42(4):308-14. PubMed ID: 8804799
[TBL] [Abstract][Full Text] [Related]
30. Resistance to antifungal agents in the critical care setting: problems and perspectives.
Martins MD; Rex JH
New Horiz; 1996 Aug; 4(3):338-44. PubMed ID: 8856751
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
Tumbarello M; Caldarola G; Tacconelli E; Morace G; Posteraro B; Cauda R; Ortona L
J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
[TBL] [Abstract][Full Text] [Related]
32. [Focusing on therapy of systemic mycoses].
Internist (Berl); 1995 Dec; 36(12 Suppl):1-12. PubMed ID: 9022383
[No Abstract] [Full Text] [Related]
33. Successful therapy of Candida albicans arthritis with a sequential intravenous amphotericin B and oral fluconazole regimen.
Barson WJ; Marcon MJ
Pediatr Infect Dis J; 1996 Dec; 15(12):1119-22. PubMed ID: 8970223
[No Abstract] [Full Text] [Related]
34. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.
Redding S; Smith J; Farinacci G; Rinaldi M; Fothergill A; Rhine-Chalberg J; Pfaller M
Clin Infect Dis; 1994 Feb; 18(2):240-2. PubMed ID: 8161633
[TBL] [Abstract][Full Text] [Related]
35. Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits.
Chemlal K; Saint-Julien L; Joly V; Farinotti R; Seta N; Yeni P; Carbon C
Antimicrob Agents Chemother; 1996 Jan; 40(1):263-6. PubMed ID: 8787921
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of fluconazole in prophylaxis and treatment of experimental Candida endocarditis.
Longman LP; Hibbert SA; Martin MV
Rev Infect Dis; 1990; 12 Suppl 3():S294-8. PubMed ID: 2184507
[TBL] [Abstract][Full Text] [Related]
37. [Esophagitis caused by fluconazole-resistant Candida albicans: therapeutic failure and in vitro correlation].
Dronda F; Rodríguez-Tudela JL; Mera P; Martínez-Suárez J
Med Clin (Barc); 1992 Jun; 99(5):199. PubMed ID: 1507907
[No Abstract] [Full Text] [Related]
38. The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient.
Kramer KM; Skaar DJ; Ackerman BH
Pharmacotherapy; 1997; 17(3):538-48. PubMed ID: 9165556
[TBL] [Abstract][Full Text] [Related]
39. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans.
Laguna F; Rodríguez-Tudela JL; Martínez-Súarez JV; Polo R; Valencia E; Díaz-Guerra TM; Dronda F; Pulido F
Clin Infect Dis; 1997 Feb; 24(2):124-30. PubMed ID: 9114134
[TBL] [Abstract][Full Text] [Related]
40. Development of Hansenula anomala infection in a child receiving fluconazole therapy.
Alter SJ; Farley J
Pediatr Infect Dis J; 1994 Feb; 13(2):158-9. PubMed ID: 8190545
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
